Sepsis and septic shock

Schweizerische Medizinische Wochenschrift

Volumn 127, Issue 12, 1997, Pages 489-499

  Zanetti, G ^a   Baumgartner, J D ^b   Glauser, M P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hopital de Zone   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN; IMIPENEM; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; HUMAN; PRACTICE GUIDELINE; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 0030895282     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. The ACCP/SCCM Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644-1655.
2. Centers for Disease Control. Increase in National Hospital Discharge Survey rates for septicemia - United States. MMWR Morb Mortal Wkly Rep 1990; 39: 909-912.
3. Rangel-Fausto MS, Pittet D, Costigan M, Hwang T, Davis CS et al.: The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 1995; 273: 117-123.
4. Parillo JE: Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113: 227-242.
5. Veterans Administration Systemic Sepsis Cooperative Study Group: Effects of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317: 659-665.
6. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz GA et al.: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.
7. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA et al.: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994; 271: 1836-1843.
8. Beck-Sague CM, Jarvis WR, the National Nosocomial Infections Surveillance System: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247-1251.
9. Brandtzaeg P, Kierulf P, Gaustad P, Shulberg A, Bruun JM et al.: Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159: 195-204.
10. van Deventer SJ, Buller HR, ten Cate JW, Sturk A, Pauw W: Endotoxemia: an early predictor of septicaemia in febrile patients. Lancet 1988/I: 605-609.
11. Marrack P, Kappler J: The staphylococcal enterotoxins and their relatives. Science 1990; 248: 705-711.
12. Pugin J, Heumann D, Tomasz A, Kravchenko UU, Akamatsu Y et al.: CD14 is a pattern recognition receptor. Immunity 1994; 1: 509-516.
13. Majcherczyk PA, Knaup M, Pugin J, Glauser MP, Moreillon P, Heumann D: CD14 dependant and independant activation of monocytes stimulated by gram-positive bacterial cell wall fragments [Abstract]. 36th Interscience Conference on Anti-microbial Agents and Chemotherapy. New Orleans, 1996: G51.
14. Spika JS, Peterson PK, Wilkinson BJ, Hammerschmidt DE, Verbrugh HA et al.: Role of peptidoglycan from Staphylococcus aureus in leukopenia, thrombocytopenia, and complement activation associated with bacteremia. J Infect Dis 1982; 146: 227-234.
15. Jacobs HS: The role of activated complement and granulocytes in shock states and myocardial infarction. J Lab Clin Med 1981; 98: 645-654.
16. 5a are associated with fatal outcome in sepsis. Am J Med 1989; 86: 20-26.
17. Kalter ES, van Dijk WC, Timmerman A, Verhoef J, Bouma BN: Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis 1983; 148: 682-691.
18. Warr TA, Mohan Rao LV, Rapaport SI: Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-1489.
19. Colman RW: The role of plasma proteases in septic shock. N Engl J Med 1989; 320: 1207-1209.
20. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD et al.: Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-1431.
21. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433.
22. Heumann D, Gallay P, Barras C, Zaech P, Ulevitch RJ et al.: Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol 1992; 148: 3505-3512.
23. Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V et al.: Soluble CD14 participates in the response of cells to lipopolysaccharide. J Immunol 1992; 176: 1665-1671.
24. Pugin J, Schurer-Maly CC, Leturcq D, Mariarty A, Ulevitch RJ et al.: Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 1993; 90: 2744-2748.
25. Landmann R, Reber AM, Sansano S, Zimmerli W: Function of soluble CD14 in serum from patients with septic shock. J Infect Dis 1996; 173: 661-668.
26. Tracey KJ, Lowry SF: The role of cytokine mediators in septic shock. Adv Surg 1990; 23: 21-26.
27. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT et al.: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330: 662-664.
28. Mathison FC, Wolfson E, Ulevitch RJ: Participation of tumor necrosis factor in the mediation of bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81: 1925-1937.
29. Beutler B, Milsark IW, Cerami A: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-871.
30. Silva AT, Bayston KF, Cohen J: Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-a in experimental gram-negative shock. J Infect Dis 1990; 162: 421-427.
31. Bagby GJ, Plessala KJ, Wilson LA, Thompson KJ, Nelson S: Divergent efficacy of antibody to tumor necrosis factor-a in intravascular and peritonitis models of sepsis. J Infect Dis 1990; 163: 83-88.
32. Echtenacher B, Falk W, Männel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762-3766.
33. Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P et al.: Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. J Immunol 1992; 148: 1890-1897.
34. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-1652.
35. Waage A, Espevik T: Interleukin-1 potentiates the lethal effect of tumor necrosis factor-alpha/cachectin in mice. J Exp Med 1988; 167: 1987-1992.
36. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319: 397-400.
37. Waage A, Halstensen A, Espevik T: Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355-357.
38. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH et al.: Prognosis values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha and interferon-gamma in the serum of patients with septic shock. J Infect Dis 1990; 161: 982-987.
39. McIntyre KW, Stepan GJ, Kolinsky KD, Benjamin WR, Plocinski JM et al.: Inhibition of interleukin-1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991; 173: 931-939.
40. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA: A specific receptor antagonist to interleukin-1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338-343.
41. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA: A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxinemia in mice. J Exp Med 1991; 173: 1029-1032.
42. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP, The Swiss-Dutch J5 Immunoglobulin Study Group: High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1991; 91: 23-29.
43. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ et al.: Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991; 21: 2883-2886.
44. Welbourn CRB, Young Y: Endotoxin, septic shock and acute lung injury: neutrophils, macrophages, and inflammatory mediators. Br J Surg 1992; 79: 998-1003.
45. Dinarello CA: The pro-inflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 1991; 163: 1177-1184.
46. Cotran RS, Pober JS: Effects of cytokines on vascular endothelium: their role in vascular and immune injury. Kidney Int 1989; 35: 969-975.
47. Chang SW, Fedderson CO, Henson PM, Voelkel NF: Platelet activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1990; 171: 439-448.
48. Vane JR, Angaard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27-36.
49. Hotchkiss RS, Parker JL, Adams HR: Inhibition of NO synthesis in septic shock. Lancet 1992; 339: 434-435.
50. Teale DM, Atkinson AM: Inhibition of nitric oxide synthesis improves survival in a murine peritonitis model of sepsis that is not cured by antibiotics alone. J Antimicrob Chemother 1992; 30: 839-842.
51. Cobb JP, Natanson C, Hoffman WD, Lodato RF, Banks S et al.: N omega amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality in awake canines challenged with endotoxin. J Exp Med 1992; 176: 1175-1182.
52. Petros A, Bennett D, Vallance P: Effect of nitric oxide synthetase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338: 1557-1558.
53. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ et al.: Altered immune response in mice lacking inducible nitric oxide synthase. Nature 1995; 375: 408-411.
54. Reines HD, Halushka PV, Cook JA, Wise WC, Rambo W: Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet 1982; 2: 174-175.
55. McCabe WR, Jackson GG: Gram-negative bacteremia. Arch Intern Med 1962; 110: 92-98.
56. Bryan CS, Reynold KL, Brenner ER: Analysis of 1186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983; 5: 629-638.
57. Bryant RE, Hood AF, Hood CE, Koenig MG: Factors affecting mortality of gram-negative bacteremia. Arch Intern Med 1971; 127: 120-128.
58. Gribble MJ, Chow AW, Naiman SC, Smith JA, Bowie WR et al.: Prospective randomized trial of piperacilline monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother 1983; 24: 388-393.
59. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D et al.: Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in non-neutropenic patients. Antimicrob Agents Chemother 1994; 38: 1309-1313.
60. Zimmerli W, Lew DP, The Swiss Society of Infectious Diseases: Use of aminoglycosides: the Swiss consensus. Schweiz Med Wochenschr 1996; 126 (Suppl. 76): 5S-8S.
61. Baumgartner JD, Heumann D, Gerain J, Weinbreck P, Grau GE et al.: Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor-a and interleukin-6. Comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med 1990; 171: 889-896.
62. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC et al.: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307: 1225-1230.
63. Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, van Melle G et al.: Prevention of gram-negative shock and death in surgical patients by prophylactic antibody to endotoxin core glycolipid. Lancet 1985; 2: 59-63.
64. J5 Study Group: Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J Infect Dis 1992; 165: 695-701.
65. Greenman RL, Schein RM, Martin MA, Wenzel RP, McIntyre HR et al.: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991; 266: 1097-1102.
66. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC et al.: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324: 429-436.
67. Mc Closkey RV, Strauber RC, Sanders C, Smith SM, Smith CR: Treatment of septic shock with human monoclonal antibody HA-IA. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994; 121: 1-5.
68. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP et al.: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23: 994-1006.
69. Stütz P, Liehl E: Lipid A analogs aimed at preventing the detrimental effects of endotoxin. In: Young LS, Glauser MP (eds): Gram-negative septicemia and septic shock. Philadelphia: WB Saunders, 1991: 847-874.
70. Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S et al.: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742.
71. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis syndrome. JAMA 1995; 273: 934-941.
72. Cohen J, Carlet J, The Intersept Study Group: Intersept: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Crit Care Med 1996; 24: 1431-1440.
73. Ashkenazi A, Masters SA, Capon DJ: Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 1991; 88: 10535-10539.
74. Peppel K, Crawford D, Beutler B: A tumor necrosis factor receptor-IgG heavy chain chimeric protein as a bivalent-antagonist of TNF activity. J Exp Med 1991; 174: 1484-1488.
75. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA et al.: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697-1702.
76. Abraham E, Glauser MP, Gelmont D, Kudsk K, Lew D et al: Ro 45-2081 (TNFR55-IgG1) in the treatment of patients with severe sepsis/septic shock: preliminary results. 3rd Annual Autumnal Sepsis Meeting, Dauville, France, 1995.
77. Fisher CJ, Slotman GJ, Opal SM, Pribble JP, Bove RC et al.: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22: 12-21.